Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Endocr Metab Immune Disord Drug Targets ; 22(13): 1276-1292, 2022.
Article in English | MEDLINE | ID: covidwho-1779865

ABSTRACT

BACKGROUND: Typical lung diseases are pneumonia, asthma, sleep apnea syndrome (SA), interstitial pneumonia (IP), lung cancer, and chronic obstructive pulmonary disease (COPD). Coronavirus disease 2019 (COVID-19) is a type of viral pneumonia. Many researchers have reported that phytochemicals (chemical compounds produced by plants) and vitamin D are useful in stimulating our immunity. This review discusses the alleviation of lung diseases by grape phytochemicals and vitamin D. DISCUSSION: Pneumonia is an acute inflammation caused by the infection of pathogens; the worst case is a fatal cytokine storm in the lung. In asthma, allergens, tobacco smoke, or air pollution may cause seizures. Lung diseases caused by lung fibrosis may manifest chronic inflammation, progress into alveolar fibrosis, and cause respiratory malfunction. SA is a lifestyle disease related to obesity and metabolic syndrome. To alleviate these symptoms, changing the eating habit is one of the strategies. Improvement in the daily lifestyle reduces the risk of lung cancer. Self-management, including nutritional management and exercise, is very important for COPD patients in addition to pharmacotherapy. CONCLUSION: The intake of grape phytochemicals and vitamin D prevents the progress of lung diseases. Both phytochemicals and vitamin D prevent the production of proinflammatory cytokine, TNF-α, that is responsible for inflammation and lung diseases. Daily intake of grape phytochemicals is important. The optimum vitamin D level in serum is > 30 ng/mL. For the prevention of lung diseases, upregulating immunity and maintaining good gut microbiota are important because gut microbiota change depending on what we eat.


Subject(s)
Asthma , COVID-19 Drug Treatment , Lung Diseases , Lung Neoplasms , Pneumonia , Pulmonary Disease, Chronic Obstructive , Vitis , Humans , Vitamin D/therapeutic use , Vitamins , Lung Diseases/drug therapy , Lung Diseases/prevention & control , Lung , Phytochemicals/therapeutic use , Inflammation
2.
Addiction ; 116(9): 2559-2571, 2021 09.
Article in English | MEDLINE | ID: covidwho-1334376

ABSTRACT

This narrative review provides a summary of the impact of tobacco smoking on the respiratory system and the benefits of smoking cessation. Tobacco smoking is one of the leading preventable causes of death world-wide and a major risk factor for lung cancer and chronic obstructive pulmonary disease. Smoking is also associated with an increased risk of respiratory infections and appears to be related to poorer outcomes among those with COVID-19. Non-smokers with second-hand smoke exposure also experience significant adverse respiratory effects. Smoking imposes enormous health- and non-health-related costs to societies. The benefits of smoking cessation, in both prevention and management of respiratory disease, have been known for decades and, to this day, cessation support remains one of the most important cost-effective interventions that health professionals can provide to people who smoke. Cessation at any age confers substantial health benefits, even in smokers with established morbidities. As other treatments for chronic respiratory disease advance and survival rates increase, smoking cessation treatment will become even more relevant. While smoking cessation interventions are available, the offer of these by clinicians and uptake by patients remain limited.


Subject(s)
Lung Diseases/complications , Lung Diseases/pathology , Smoking Cessation , Tobacco Use Disorder/complications , Tobacco Use Disorder/pathology , Humans , Lung/pathology , Lung Diseases/prevention & control , Tobacco Use Disorder/therapy
3.
Biochimie ; 187: 94-109, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1252495

ABSTRACT

Despite the development of a number of vaccines for COVID-19, there remains a need for prevention and treatment of the virus SARS-CoV-2 and the ensuing disease COVID-19. This report discusses the key elements of SARS-CoV-2 and COVID-19 that can be readily treated: viral entry, the immune system and inflammation, and the cytokine storm. It is shown that the essential nutrients zinc, ω-3 polyunsaturated fatty acids (PUFAs), vitamin D and magnesium provide the ideal combination for prevention and treatment of COVID-19: prevention of SARS-CoV-2 entry to host cells, prevention of proliferation of SARS-CoV-2, inhibition of excessive inflammation, improved control of the regulation of the immune system, inhibition of the cytokine storm, and reduction in the effects of acute respiratory distress syndrome (ARDS) and associated non-communicable diseases. It is emphasized that the non-communicable diseases associated with COVID-19 are inherently more prevalent in the elderly than the young, and that the maintenance of sufficiency of zinc, ω-3 PUFAs, vitamin D and magnesium is essential for the elderly to prevent the occurrence of non-communicable diseases such as diabetes, cardiovascular diseases, lung diseases and cancer. Annual checking of levels of these essential nutrients is recommended for those over 65 years of age, together with appropriate adjustments in their intake, with these services and supplies being at government cost. The cost:benefit ratio would be huge as the cost of the nutrients and the testing of their levels would be very small compared with the cost savings of specialists and hospitalization.


Subject(s)
COVID-19/prevention & control , Fatty Acids, Omega-3/therapeutic use , Magnesium/therapeutic use , Noncommunicable Diseases/prevention & control , Vitamin D/therapeutic use , Zinc/therapeutic use , Aged , COVID-19/therapy , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/therapy , Cytokine Release Syndrome/therapy , Diabetes Mellitus/prevention & control , Diabetes Mellitus/therapy , Humans , Inflammation/therapy , Lung Diseases/prevention & control , Lung Diseases/therapy , Neoplasms/prevention & control , Neoplasms/therapy , Noncommunicable Diseases/therapy , Nutritional Status , SARS-CoV-2 , Vitamins/therapeutic use
4.
Clin Chest Med ; 41(4): 605-621, 2020 12.
Article in English | MEDLINE | ID: covidwho-896784

ABSTRACT

Computer and information systems can improve occupational respiratory disease prevention and surveillance by providing efficient resources for patients, workers, clinicians, and public health practitioners. Advances include interlinking electronic health records, autocoding surveillance data, clinical decision support systems, and social media applications for acquiring and disseminating information. Obstacles to advances include inflexible hierarchical coding schemes, inadequate occupational health electronic health record systems, and inadequate public focus on occupational respiratory disease. Potentially transformative approaches include machine learning, natural language processing, and improved ontologies.


Subject(s)
Informatics/methods , Lung Diseases/diagnosis , Lung Diseases/prevention & control , Occupational Diseases/diagnosis , Occupational Diseases/prevention & control , Occupational Exposure/adverse effects , Humans , Machine Learning
5.
Ann Ig ; 33(6): 615-627, 2021.
Article in English | MEDLINE | ID: covidwho-1168080

ABSTRACT

BACKGROUND: The outbreak of Coronavirus disease 2019 (COVID-19) made imperative the use of protective devices as a source control tool. As there is no definite antiviral treatment and effective vaccine, the only efficient means of protecting and mitigating infectious contagion has been the use of personal protective equipment, especially by healthcare workers. However, masks affect the humidification process of inhaled air, possibly leading to a basal inflammatory state of the upper airways. STUDY DESIGN: This is a single-center observational study conducted at the University Hospital of Catania from April 1, 2020, to June 31, 2020. METHODS: We analyzed the role of protective masks on the elimination of upper airways complaints in healthcare workers of the University Hospital of Catania. We evaluated 277 subjects through a self-administered 17 item questionnaire based on respiratory, work performance and health-related quality of life domains. RESULTS: A higher prevalence of nasal and ocular symptoms, perceived reduced work performance, difficulty in concentrating, and sleep disorders were found. After two weeks adhering to a list of good practices that we recommended, significant reversibility of the symptoms investigated and work performance enhancement were observed. CONCLUSIONS: Despite clinical complaints related to personal protective equipment, effective amelioration through usage rules is easily obtained. Given the essential use of protective masks, healthcare workers have to adhere to appropriate work and safety prevention rules.


Subject(s)
COVID-19/prevention & control , Health Personnel , Masks/adverse effects , Occupational Diseases/etiology , Quality of Life , Work Performance , Adult , COVID-19/transmission , Eye Diseases/etiology , Eye Diseases/prevention & control , Female , Guideline Adherence , Humans , Lung Diseases/etiology , Lung Diseases/prevention & control , Male , Masks/standards , Middle Aged , Nose Diseases/etiology , Nose Diseases/prevention & control , Occupational Diseases/prevention & control , Personal Protective Equipment/standards , Surveys and Questionnaires
6.
Am J Physiol Gastrointest Liver Physiol ; 320(4): G586-G600, 2021 04 01.
Article in English | MEDLINE | ID: covidwho-1050415

ABSTRACT

As countries continue to industrialize, major cities experience diminished air quality, whereas rural populations also experience poor air quality from sources such as agricultural operations. These exposures to environmental pollution from both rural and populated/industrialized sources have adverse effects on human health. Although respiratory diseases (e.g., asthma and chronic obstructive pulmonary disease) are the most commonly reported following long-term exposure to particulate matter and hazardous chemicals, gastrointestinal complications have also been associated with the increased risk of lung disease from inhalation of polluted air. The interconnectedness of these organ systems has offered valuable insights into the roles of the immune system and the micro/mycobiota as mediators of communication between the lung and the gut during disease states. A topical example of this relationship is provided by reports of multiple gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19), whereas the rapid transmission and increased risk of COVID-19 has been linked to poor air quality and high levels of particulate matter. In this review, we focus on the mechanistic effects of environmental pollution on disease progression with special emphasis on the gut-lung axis.


Subject(s)
COVID-19 , Environmental Exposure , Gastrointestinal Diseases , Lung Diseases , Air Pollution , COVID-19/epidemiology , COVID-19/prevention & control , Comorbidity , Disease Progression , Environmental Exposure/adverse effects , Environmental Exposure/prevention & control , Gastrointestinal Diseases/epidemiology , Gastrointestinal Diseases/prevention & control , Humans , Lung Diseases/epidemiology , Lung Diseases/prevention & control , Public Health , SARS-CoV-2
7.
J Neuroimmune Pharmacol ; 16(1): 59-70, 2021 03.
Article in English | MEDLINE | ID: covidwho-1018438

ABSTRACT

COVID-19 is an infectious respiratory illness caused by the virus strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and until now, there is no effective therapy against COVID-19. Since SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) for entering into host cells, to target COVID-19 from therapeutic angle, we engineered a hexapeptide corresponding to the ACE2-interacting domain of SARS-CoV-2 (AIDS) that inhibits the association between receptor-binding domain-containing spike S1 and ACE-2. Accordingly, wild type (wt), but not mutated (m), AIDS peptide inhibited SARS-CoV-2 spike S1-induced activation of NF-κB and expression of IL-6 in human lungs cells. Interestingly, intranasal intoxication of C57/BL6 mice with recombinant SARS-CoV-2 spike S1 led to fever, increase in IL-6 in lungs, infiltration of neutrophils into the lungs, arrhythmias, and impairment in locomotor activities, mimicking some of the important symptoms of COVID-19. However, intranasal treatment with wtAIDS, but not mAIDS, peptide reduced fever, protected lungs, improved heart function, and enhanced locomotor activities in SARS-CoV-2 spike S1-intoxicated mice. Therefore, selective targeting of ACE2-to-SARS-CoV-2 interaction by wtAIDS may be beneficial for COVID-19.


Subject(s)
Angiotensin-Converting Enzyme 2/therapeutic use , COVID-19 Drug Treatment , COVID-19/complications , Fever/drug therapy , Fever/etiology , Heart Diseases/etiology , Heart Diseases/prevention & control , Inflammation/drug therapy , Inflammation/etiology , Lung Diseases/etiology , Lung Diseases/prevention & control , Peptide Fragments/therapeutic use , Administration, Intranasal , Animals , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/prevention & control , COVID-19/pathology , Female , Heart Diseases/pathology , Interleukin-6/metabolism , Lung Diseases/pathology , Male , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Neutrophil Infiltration/drug effects , Spike Glycoprotein, Coronavirus/toxicity
8.
Clin Appl Thromb Hemost ; 26: 1076029620936350, 2020.
Article in English | MEDLINE | ID: covidwho-639157

ABSTRACT

This practical guidance, endorsed by the Brazilian Society of Thrombosis and Hemostasis and The Brazilian Society of Angiology and Vascular Surgery, the International Union of Angiology and the European Venous Forum, aims to provide physicians with clear guidance, based on current best evidence-based data, on clinical strategies to manage antithrombotic strategies in patients with coronavirus disease 2019.


Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Pandemics , Pneumonia, Viral/complications , Practice Guidelines as Topic , Thrombophilia/therapy , Thrombosis/prevention & control , Anticoagulants/therapeutic use , Biomarkers , COVID-19 , Clinical Trials as Topic , Coronavirus Infections/blood , Cytokine Release Syndrome/blood , Cytokine Release Syndrome/etiology , Disease Management , Endothelium, Vascular/physiopathology , Endothelium, Vascular/virology , Evidence-Based Medicine , Fibrin Fibrinogen Degradation Products/analysis , Humans , Lung Diseases/etiology , Lung Diseases/prevention & control , Pneumonia, Viral/blood , Pulmonary Veins , SARS-CoV-2 , Thrombophilia/etiology , Thrombophlebitis/etiology , Thrombophlebitis/prevention & control , Thrombosis/etiology , Venous Thromboembolism/etiology , Venous Thromboembolism/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL